Biodesix, Inc. $BDSX Shares Sold by Monashee Investment Management LLC

Monashee Investment Management LLC cut its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 95.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 99,996 shares of the company’s stock after selling 1,900,004 shares during the quarter. Monashee Investment Management LLC’s holdings in Biodesix were worth $755,000 at the end of the most recent quarter.

Separately, XTX Topco Ltd boosted its stake in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the last quarter. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BDSX. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Biodesix in a research note on Tuesday, February 17th. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Insider Buying and Selling

In related news, Director Jack W. Schuler acquired 20,000 shares of Biodesix stock in a transaction that occurred on Monday, January 26th. The stock was acquired at an average price of $11.80 per share, for a total transaction of $236,000.00. Following the transaction, the director directly owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This trade represents a 1.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Scott Hutton sold 3,559 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. The trade was a 7.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have bought 182,465 shares of company stock worth $2,084,616 and have sold 10,999 shares worth $116,095. 30.10% of the stock is currently owned by corporate insiders.

Biodesix Stock Up 7.8%

Shares of NASDAQ:BDSX opened at $15.33 on Friday. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $19.13. The company’s fifty day moving average is $9.55 and its two-hundred day moving average is $8.37. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $122.03 million, a price-to-earnings ratio of -3.16 and a beta of 0.67.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.56. Biodesix had a negative net margin of 39.85% and a negative return on equity of 1,009.88%. The business had revenue of $28.76 million during the quarter, compared to the consensus estimate of $26.25 million. Equities analysts anticipate that Biodesix, Inc. will post -0.35 EPS for the current year.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.